Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,039Revenue $M3.6Net Margin (%)-3,969.3Z-Score33.0
Enterprise Value $M1,815EPS $-1.3Operating Margin %-4,122.2F-Score5
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-3,969.3Higher ROA y-yY
Price/Book10.010-y EBITDA Growth Rate %0Quick Ratio10.6Cash flow > EarningsY
Price/Sales9045-y EBITDA Growth Rate %0Current Ratio10.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-38.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-42.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M89.6ROI % (ttm)-48.8Gross Margin Increase y-yY

Gurus Latest Trades with CLDX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CLDXJean-Marie Eveillard 2014-12-31 Add0.01%$12.55 - $20.93
($16.61)
$ 25.5454%Add 123.82%559,542
CLDXJean-Marie Eveillard 2014-09-30 Buy 0.01%$12.05 - $17.57
($14.51)
$ 25.5476%New holding, 250000 sh.250,000
CLDXJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$16.95 - $31.59
($25.6)
$ 25.540%Sold Out0
CLDXAndreas Halvorsen 2013-12-31 Sold Out -0.13%$21.51 - $36.71
($25.51)
$ 25.540%Sold Out0
CLDXJean-Marie Eveillard 2013-12-31 Reduce-0.04%$21.51 - $36.71
($25.51)
$ 25.540%Reduce -75.45%135,000
CLDXAndreas Halvorsen 2013-09-30 Buy 0.13%$18.37 - $36.01
($22.76)
$ 25.5412%New holding, 672513 sh.672,513
CLDXJean-Marie Eveillard 2013-06-30 Reduce-0.02%$11.01 - $16.09
($13.13)
$ 25.5494%Reduce -45.89%665,560
CLDXJean-Marie Eveillard 2012-06-30 Add0.02%$3.9 - $5.26
($4.39)
$ 25.54482%Add 260.87%1,660,000
CLDXGeorge Soros 2012-06-30 Sold Out -0.06%$3.9 - $5.26
($4.39)
$ 25.54482%Sold Out0
CLDXGeorge Soros 2012-03-31 Buy 0.06%$2.77 - $5.46
($4)
$ 25.54538%New holding, 803200 sh.803,200
CLDXJean-Marie Eveillard 2012-03-31 Add0.01%$2.77 - $5.46
($4)
$ 25.54538%Add 360%460,000
CLDXJean-Marie Eveillard 2011-12-31 Reduce$2.11 - $3.21
($2.7)
$ 25.54846%Reduce -71.43%100,000
CLDXJean-Marie Eveillard 2011-06-30 Buy 0.01%$3.03 - $4.46
($3.75)
$ 25.54581%New holding, 350000 sh.350,000
CLDXJean-Marie Eveillard 2010-03-31 Sold Out $4.35 - $6.39
($4.93)
$ 25.54418%Sold Out0
CLDXJean-Marie Eveillard 2009-12-31 Buy $4.2 - $5.66
($4.78)
$ 25.54434%New holding, 100000 sh.100,000
CLDXJean-Marie Eveillard 2009-09-30 Sold Out $4.95 - $7.93
($6.35)
$ 25.54302%Sold Out0
CLDXJean-Marie Eveillard 2009-06-30 Buy $6.81 - $11.22
($8.56)
$ 25.54198%New holding, 50000 sh.50,000
CLDXJohn Hussman 2009-06-30 Sold Out $6.81 - $11.22
($8.56)
$ 25.54198%Sold Out0
CLDXJohn Hussman 2008-12-31 Buy $4.94 - $7.81
($6.3)
$ 25.54305%New holding, 13000 sh.13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CLDX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CLDX Jean-Marie Eveillard 2014-12-31559,5420.620.03+123.82%
Premium Most recent portfolio changes are included for Premium Members only!


CLDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
van den Broek RichardDirector 2014-12-17Sell0$0view
CATLIN AVERY WSr. VP & CFO 2013-12-06Sell183,333$24.54.24view
ELLBERGER LARRYDirector 2013-12-06Sell17,728$24.54.24view
PENNER HARRY JRDirector 2013-12-06Sell17,728$24.54.24view
LIPTON KAREN SHOOSDirector 2013-12-06Sell17,728$24.54.24view
KELER TIBORSr. VP & CSO 2011-08-11Buy5,000$2.5921.6view
Marucci Anthony SPresident & CEO 2011-08-09Buy15,000$2.41959.75view
CATLIN AVERY WSr. VP & CFO 2011-08-09Buy2,000$2.39968.62view
Davis Thomas AndrewSr. VP & CMO 2010-09-16Buy2,500$3.77577.45view
LIPTON KAREN SHOOSDirector 2010-09-16Buy3,000$3.74582.89view

Press Releases about CLDX :

    Quarterly/Annual Reports about CLDX:

    News about CLDX:

    Articles On GuruFocus.com
    Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
    CLDX up 223%, Cohen Gains Big Apr 23 2013 
    Steve Cohen Increases Celldex Up 145% Apr 06 2013 
    comment on CLDX Mar 06 2013 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
    Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) May 06 2010 
    cooldecency99 note on CLDX May 01 2010 


    More From Other Websites
    Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares Feb 27 2015
    Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences Feb 27 2015
    10-K for Celldex Therapeutics, Inc. Feb 26 2015
    Celldex Therapeutics Prices Public Offering of Common Stock Feb 25 2015
    Celldex Therapeutics Announces Proposed Public Offering of Common Stock Feb 25 2015
    Celldex Therapeutics Prices Public Offering of Common Stock Feb 25 2015
    6 stocks to watch Feb 25 2015
    Celldex Therapeutics (CLDX) Stock Rises Today on Rintega FDA Designation, Fourth-Quarter Earnings Feb 24 2015
    Celldex reports 4Q loss Feb 24 2015
    Celldex reports 4Q loss Feb 24 2015
    Celldex Therapeutics (CLDX) Wider-than-Expected Loss in Q4 - Tale of the Tape Feb 24 2015
    CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 24 2015
    Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment... Feb 24 2015
    Celldex Reports Fourth Quarter and Year-End 2014 Results Feb 24 2015
    Q4 2014 Celldex Therapeutics Inc Earnings Release - Before Market Open Feb 24 2015
    Celldex Reports Fourth Quarter and Year-End 2014 Results Feb 24 2015
    Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog Feb 23 2015
    Celldex Therapeutics Shares Shooting Higher Feb 23 2015
    Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment... Feb 23 2015
    Celldex to Report Fourth Quarter and Fiscal 2014 Business/Financial Results and Host 2015 Corporate... Feb 19 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK